The Efficacy and Safety of Weekly 35-Mg Risedronate Dosing Regimen for Chinese Postmenopausal Women with Osteoporosis or Osteopenia: 1-Year Data.
Jie-mei Gu,Li Wang,Hua Lin,De-cai Chen,Hai Tang,Xiao-lan Jin,Wei-bo Xia,Yun-qiu Hu,Wen-zhen Fu,Jin-wei He,Hao Zhang,Chun Wang,Hua Yue,Wei-wei Hu,Yu-juan Liu,Zhen-lin Zhang
DOI: https://doi.org/10.1038/aps.2015.30
2015-01-01
Abstract:Aim: Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopausal women with osteoporosis or osteopenia. Methods: Postmenopausal women with primary osteoporosis or osteopenia were randomly assigned to the weekly group or daily group ( n =145 for each) that received oral risedronate 35 mg once a week or 5 mg daily, respectively, for 1 year. The subjects' bone mineral densities (BMDs), bone turnover markers (P1NP and β-CTX), new vertebral fractures, and adverse events were assessed at baseline and during the treatments. Results: All subjects in the weekly group and 144 subjects in the daily group completed the study. The primary efficacy endpoint after 1 year, ie the mean percent changes in the lumbar spine BMD (95% CI) were 4.87% (3.92% to 5.81%) for the weekly group and 4.35% (3.31% to 5.39%) for the daily group. The incidences of clinical adverse events were 48.3% in the weekly group and 54.2% in the daily group. Conclusion: The weekly 35-mg and daily 5-mg risedronate dosing regimens during 1 year of follow-up show similar efficacy in improving BMDs and biochemical markers of bone turnover in Chinese postmenopausal women with osteoporosis or osteopenia. Moreover, the two dosing regimens exhibit similar safety and tolerability.